Details for Patent: 12,257,236
✉ Email this page to a colleague
Which drugs does patent 12,257,236 protect, and when does it expire?
Patent 12,257,236 protects LIKMEZ and is included in one NDA.
This patent has five patent family members in five countries.
Summary for Patent: 12,257,236
| Title: | Oral formulations of metronidazole and methods of treating an infection using same |
| Abstract: | The present disclosure provides oral pharmaceutical compositions comprising: 1) metronidazole or a pharmaceutically acceptable salt thereof; and magnesium aluminum silicate; or 2) metronidazole or a pharmaceutically acceptable salt thereof; magnesium aluminum silicate; and a flavoring agent. Methods of treating infection utilizing the oral pharmaceutical compositions are also provided. |
| Inventor(s): | Bernard J. Guarino, Jr., Jamie L. Doran, Zorana Radovic, Kevin Sullivan, Armand Louis Balboni |
| Assignee: | Appili Therapeutics Inc |
| Application Number: | US18/072,154 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,257,236
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | 12,257,236 | ⤷ Start Trial | Y | TREATMENT OF TRICHOMONIASIS IN ADULTS | ⤷ Start Trial | |||
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | 12,257,236 | ⤷ Start Trial | Y | TREATMENT OF AMEBIASIS IN ADULTS AND PEDIATRIC PATIENTS | ⤷ Start Trial | |||
| Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | 12,257,236 | ⤷ Start Trial | Y | TREATMENT OF ANAEROBIC BACTERIAL INFECTIONS IN ADULTS | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,257,236
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112020014376 | ⤷ Start Trial | |||
| Canada | 3087789 | ⤷ Start Trial | |||
| European Patent Office | 3768321 | ⤷ Start Trial | |||
| Mexico | 2020007494 | ⤷ Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
